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Abstract
Background: 6-[Bis(carboxymethyl)amino]-1,4-bis(carboxymethyl)-6-methyl-1,4-diazepane (AAZTA ) is a promising
chelator with potential advantages over 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for
radiopharmaceutical applications. Its mesocyclic structure enables fast radiolabelling under mild conditions with
trivalent metals including not only 68Ga for positron emission tomography (PET) but also 177Lu and 111In for single-
photon emission computed tomography (SPECT) and radionuclide therapy. Here, we describe the evaluation of a
bifunctional AAZTA derivative conjugated to a model minigastrin derivative as a potential theranostic agent.
Methods: An AAZTA derivative with an aliphatic C9 chain as linker was coupled to a minigastrin, namely [AAZTA
0,
D-Glu1, desGlu2–6]-minigastrin (AAZTA-MG), and labelled with 68Ga, 177Lu and 111In. The characterisation in vitro
included stability studies in different media and determination of logD (octanol/PBS). Affinity determination (IC50)
and cell uptake studies were performed in A431-CCK2R cells expressing the human CCK2 receptor. μPET/CT and
ex vivo biodistribution studies were performed in CCK2 tumour xenograft-bearing nude mice and normal mice.
Results: AAZTA-MG showed high radiochemical yields for 68Ga (>95 %), 177Lu (>98 %) and 111In (>98 %). The logD
value of −3.7 for both [68Ga]- and [177Lu]-AAZTA-MG indicates a highly hydrophilic character. Stability tests showed
overall high stability in solution with some degradation in human plasma for [68Ga]- and transchelation towards
DTPA for and [177Lu]-AAZTA-MG. An IC50 value of 10.0 nM was determined, which indicates a high affinity for the
CCK2 receptor. Specific cell uptake after 60 min was >7.5 % for [68Ga]-AAZTA-MG and >9.5 % for [177Lu]-AAZTA-MG,
comparable to other DOTA-MG-analogues. μPET/CT studies in CCK2 receptor tumour xenografted mice not only
revealed high selective accumulation in A431-CCK2R positive tumours of 68Ga-labelled AAZTA-MG (1.5 % ID/g in
1 h post injection) but also higher blood levels as corresponding DOTA-analogues. The 111In-labelled peptide had a
tumour uptake of 1.7 % ID/g. Biodistribution in normal mice with the [177Lu]-AAZTA-MG showed a considerable
uptake in intestine (7.3 % ID/g) and liver (1.5 % ID/g).
Conclusion: Overall, AAZTA showed interesting properties as bifunctional chelator for peptides providing mild
radiolabelling conditions for both 68Ga and trivalent metals having advantages over the currently used chelator
DOTA. Studies are ongoing to further investigate in vivo targeting properties and stability issues and the influence
of spacer length on biodistribution of AAZTA.
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Background
With the increasing number of applications for peptide-
based radiopharmaceuticals, new radiolabelling strategies
are of high interest in particular for “theranostic” agents
[1], which combine the modalities of therapy and diag-
nostic imaging [2]. The theranostic principle is unique
for radiopharmeuticals by exchanging, for example 68Ga
for diagnostic purposes by 177Lu as a therapeutic coun-
terpart for the same targeting vector, such as a peptide,
thereby translating the diagnostic molecular character-
isation into a treatment opportunity for the patient. One
challenge in this case is varying labelling properties for
different radionuclides. Current chelators like 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
have certain limitations [3], in particular providing dif-
ferent coordinations for different metals and requiring
high temperatures for radiolabelling. Other chelators
such as 1,4,7-triazacyclononane, 1-glutaric acid-4,7
acetic acid (NODAGA) [4] have shown the potential for
convenient preparation of 68Ga-radiopharmaceuticals at
room temperature; however, they cannot be used for
other trivalent metals, in particular, those for radio-
nuclide therapy applications. A novel and versatile alter-
native bifunctional chelator for radiopharmaceutical
applications is 6-[bis(carboxymethyl)]amino]-6-(9-car-
boxynonyl)-1,4-diazepane-1,4-diacetic acid, tetra-t-butyl
ester (AAZTA) [5]. AAZTA is a heptadentate ligand,
based on the perhydro-1,4-diazepine scaffold enabling
rapid metal coordination under mild conditions. It was
first developed for magnetic resonance imaging (MRI)
applications as a chelator for gadolinium [6], but showed
significant affinity for several other metal ions [7]. Re-
cently AAZTA has been proposed as potential chelator
for 68Ga and PET applications [8] and has been used for
the development of an RGD peptide conjugate as a com-
bined PET/MRI probe radiolabelled with 68Ga [9].
Advantages of the AAZTA chelator are based on its
mesocyclic structure which enables labelling of different
radioisotopes at room temperature (RT). This allows ap-
plication also for heat or oxidation sensitive peptides or
other biomolecules.
We were not only interested in the application of
AAZTA as bifunctional chelator for potential theranostic
applications, allowing radiolabelling with 68Ga for positron
emission tomography (PET), but also other trivalent
radiometals such as 111In for single-photon emission com-
puted tomography (SPECT) and 177Lu for therapeutic ap-
plications. We chose the minigastrin11 (MG11) analogue
([D-Glu1, desGlu2–6]−minigastrin, minigastrin = Glu-Glu-
Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) as
a model targeting sequence which has been widely charac-
terised with other chelators including HYNIC and DOTA
[10, 11]. Especially, DOTA shows sensitivity towards harsh
radiolabelling conditions, in particular, heat due to the
easily oxidised Met-residue in the peptide sequence. Mini-
gastrin analogues are also very interesting because of their
targeting properties to the cholecystokinin 2 receptor,
which is overexpressed in various tumour tissue-like me-
dullary thyroid carcinoma (MTC) and gastrointestinal
stromal tumours (GIST). We here report on major char-
acteristics of an AAZTA-MG conjugate, namely
[AAZTA0, D-Glu1, desGlu2–6]-minigastrin (AAZTA-MG),




For solid-phase peptide synthesis (SPPS), a Rink amide
MBHA resin (100–200 mesh, Novabiochem, La Jolla,
CA, USA) with a 9-Fluorenylmethoxycarbonyl (Fmoc)
protective group at the N-terminal end was used. All
amino acids (Novabiochem) were also protected by
Fmoc at the amino side and the carboxyl-, amine-, hy-
droxyl groups, if existing, by an additional protecting
group. Coupling reagents 1-Hydroxy-7-azabenzotriazole
(HOAt) and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetra-
methyluronium hexafluorophosphate (HATU) were pur-
chased from GenScript Corporation (Piscataway, NJ,
USA). All other chemicals were obtained from VWR
International GmbH (Vienna, Austria) or Sigma-Aldrich
Handels GmbH (Vienna, Austria). 6-[Bis(carboxymethy-
l)]amino]-6-(9-carboxynonyl)-1,4-diazepane-1,4-diacetic
acid, tetra-t-butyl ester (CN-AAZTA(tBu)4) was pre-
pared according to [6].
68Ga-chloride was obtained from a commercial 68Ge/
68Ga-generator (Modell IGG100, Eckert & Ziegler Iso-
tope products, Berlin, Germany) with a nominal activity
of 1850 MBq. For elution of the generator, 0.1 M HCl
(Rotem Industries, Israel) was used. 177Lu-chloride in
0.04 N HCl was obtained from ITG (Munich, Germany)
and 111In-chloride in 0.05 N HCl from Mallinckrodt
Medical (Petten, NL).
Analytical methods
Reversed-phase high-performance liquid chromatog-
raphy (RP-HPLC) analysis was performed with an Ul-
tiMate 3000 RS UHPLC pump, UltiMate 3000 RS
Column Compartment (column oven temperature was
set at 25 °C), UltiMate 3000 Variable Wavelength
Detector (Dionex, Germering, Germany) and a radio
detector (GabiStar, Raytest; Straubenhardt, Germany).
An ACE 3 μm C18 150 × 3.0 mm (ACE, Aberdeen,
Scotland) with a flow rate of 0.6 mL/min, and UV
detection at 220 nm was used. The single runs were
performed with the following acetonitrile (ACN)/H2O/
0.1 % trifluoroacetic acid (TFA) gradient: 0.0–1.0 min 0 %
ACN, 1.0–10.0 min 0–50 % ACN, 10.0–11.0 min 50–80 %
ACN, 11.0–13.0 min 80 % ACN.
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Purification was performed by preparative HPLC system
(Gilson 322 Pump, Gilson UV/VIS-155) with an Eurosil
Bioselect 300 × 8 mm (DF 156) and an Eurosil Bioselect
300–5 C18 A pre-column. A flow rate of 2 mL/min and
UV detection at 220 nm with the following ACN/H2O/
0.1 % TFA gradient was applied: 0.0–1.0 min 20 % ACN,
1.0–25.0 min 20–60 % ACN, 25.0–26.0 min 60 % CAN.
The single fractions were collected by a PrepFC™ auto-
matic fraction collector (Gilson, Middleton, WI, USA).
Thin layer chromatography (TLC) analysis was per-
formed with silica gel impregnated glass fibre sheets
(ITLC-SG stripes; Varian, Lake Forest, CA, USA) as sta-
tionary phase and sodium citrate monohydrate (0.21 g/
mL, pH 5) as mobile phase and analysed using TLC
scanner (Scan-RAM™, LabLogistic, Sheffield, UK).
The radioactivity of all samples was measured in a
2480 Automatic Gamma counter Wizard2 3” (Perkin
Elmer, Waltham, MA, USA).
Peptide analysis by mass spectrometry
For mass spectrometry a CESI 8000 (Sciex, Brea, CA,
USA) equipped with a polyethyleneimine-coated capil-
lary (total length; 100 cm, i.d.; 30 μm, o.d.; 150 μm) was
coupled via an ESI module to an LTQ Orbitrap XL ETD
(Thermo Scientific, Vienna, Austria) [12]. Peptides were
diluted in 0.1 % formic acid and analysed by direct infu-
sion mass spectrometry using a flow rate of 200 nL/min.
Spectra were acquired in the Orbitrap at a resolution of
R = 60,000; the AGC target value was 1,000,000; max-
imum ionization time was set to 100 ms.
Peptide synthesis and AAZTA coupling
Synthesis of AAZTA-MG (Fig. 1) was performed using
an Fmoc SPPS technique. Furthermore, 125 mg of Rink
Amide resin (62.5 μmol) and 10 mL of dichloromethane
(DCM) were mixed in a reaction tube. After a washing
step with dimethylformamide (DMF) (3× with 10 mL for
3 min), the Fmoc protected group was cleaved by adding
10 mL of piperidine/DMF (v/v; 20/80) (2× with 10 mL
for 5 min, 1× with 10 mL for 15 min) and another wash-
ing step with N-Methyl-2-pyrrolidone (NMP) (6× with
10 mL for 3 min).
Amino acid (fivefold excess) coupling was performed
by HATU/HOAt activation in NMP at pH 8 to 9 and a
reaction time of 1 to 4 h. For the amino acids Asp and
Glu, an OtBu side chain protection was applied, whereas
for Trp BOC and for Tyr, tBu protection groups were
used.
After removing the last Fmoc protection group
from the final amino acid, the AAZTA-C9 chelator
CN-AAZTA(tBu)4 was coupled using a threefold ex-
cess of the chelator activated by HATU/HOAt in
10 mL NMP for 10 min at pH >10. The solution was
then shaken for 18 h overnight and washed as a last
step with NMP.
To cleave the peptide from the resin, a solution of
TFA/Triisopropylsilane/H2O (v/v/v; 95/2.5/2.5) was
added and left to react for 1 h, followed by ether precipi-
tation and a drying step. The resulting peptide was dis-
solved in 35 % ethanol, purified by RP-HPLC and
characterised by ESI-MS (see also Additional file 1).
Fig. 1 Structure of AAZTA-MG (D-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)
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Radiolabelling
All radiolabelling experiments were performed at RT
with reaction times of about 10 min. The radiolabelling
yield was determined by radio-HPLC or radio-ITLC.
For 68Ga-labelling 10 μg AAZTA-MG (20 μL, 0.5 mg/
mL), 30 μL sodium acetate trihydrate buffer (1.14 M,
pH 4.5) and 100 μL of 68Ga-eluate (0.1 M HCl, 25 MBq)
were used. 177Lu-labelling was done with 10 μg AAZTA-
MG (20 μL, 0.5 mg/mL), 40 μL ascorbic acid buffer
(300 μM, pH 4.5) and 40 μL of 177Lu (0.05 M HCl,
60 MBq). Labelling of AAZTA-MG with 111In-chloride
was performed using 10 μg peptide (20 μL, 0.5 mg/mL),
100 μL ascorbic acid buffer (300 μM; pH 4.5), and 30 μL
111In (0.05 M HCl, 30 MBq). For receptor binding affin-
ity studies (IC50), the -minigastrin analogue CP04
[1,4,7,10-tetraazacyclododecane-N,N’,N”,N’”-tetraacetic acid
(DOTA)-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-
Gly-Trp-Met-Asp-Phe-NH2, PiCHEM, Graz, Austria)
was labelled with 177Lu as follows: 10 μg AAZTA-MG
(10 μL, 1 mg/mL), 50 μL ascorbic acid buffer (300 μM;
pH 4.5), and 10 μL 177Lu (0.05 M HCl, 160 MBq) were left
to react for 10 min at RT.
Distribution coefficient (logD)
50 μL of radiolabelled peptide solution (approx. 2 MBq;
330 pmol peptide) was added to 450 μL PBS and 500 μL
octanol. The mixture was vortexed using a MS 3 basic
vortexer (IKA, Staufen, Germany) for 20 min at 1400 rpm
and hereafter centrifuged for 2 min at 4500 rpm. Out
of both phases, 200 μL of sample were transferred
into plastic vials, measured in the gamma counter
and logD values were then calculated.
Stability assay
To verify the stability of radiolabelled AAZTA-MG, tests
were performed in the following four different media:
ethylenediaminetetraacetic acid (EDTA), diethylenetria-
minepentaacetic acid (DTPA) solutions in 1000-fold ex-
cess over the peptide, human plasma and PBS as
control. The labelling solution was diluted to 1 mL and
50 μL of that solution incubated with 150 μL of the
challenging solution. After 60, 120 and 240 min, 5 μL of
the sample were analysed by TLC with citrate buffer
(0.21 g/mL, pH = 5) as mobile phase. The strips were cut
into three evenly divided pieces and measured in a gamma
counter to determine the free radioligand (solvent front)
to labelled peptide (origin) ratio.
Protein binding
For this test radiolabelled peptide solution was diluted to
1 mL with PBS. From this solution, 150 μL were incubated
in 850 μL fresh human plasma and in 850 μL of PBS as
control. After 30, 60 and 120 min, 25 μL of the solution
were analysed by size-exclusion chromatography using
MicroSpin G-50 Columns (Sephadex G-50, GE Health-
care, Vienna, Austria). First, the MicroSpin columns were
centrifuged at 2000 crf for 1 min to remove the storage
buffer, and then, the 25 μL were added and centrifuged
again for 1 min with 2000 crf. Both, column (containing
the “free” radiolabelled peptide) and eluate (containing
the protein-bound fraction), were measured in the
gamma counter.
Receptor binding affinity (IC50)
A human transfected cell line was used with two differ-
ent expression properties of the cholecystokinin (CCK)
receptor: CCK2+ (A431-309CCK2R; receptor-positive
cells) and CCK2− (A431-609; mock transfected control
cells) cells [13].
In vitro binding affinities of AAZTA-MG were deter-
mined by using CCK2+ cell membranes and 177Lu-la-
belled CP04 (a minigastrin analogue with high affinity to
the CCK2 receptor) as radioligand incubated with increas-
ing concentrations of the competitor. As competitor
AAZTA-MG and [natLu]- and [natGa]-AAZTA-MG were
used. The latter were prepared by incubating 10 μg
AAZTA-MG with a tenfold molar excess of Lu-chloride
in ascorbic acid buffer and 100 μl Ga-bromide in sodium
acetate buffer for 10 min, respectively.
The 96-well plates (MulitScreen Filter Plates, HTS)
were washed with 250 μL 10 mM TRIS buffered saline
(pH 7.3). CCK2 cells were diluted in 20 mM HEPES buf-
fer containing 1 M MgCl2—in this hypoosmotic solution
the cells were cracked releasing free membranes. Then,
150 μL of cell solution (ca. 8 × 105 cells/mL was added
into each well and incubated with 50 μL 177Lu-labelled
CP04 (0.97 nM) for 10 min at RT. Hereafter, 50 μL of
AAZTA-MG was added at increasing concentrations
(0.01–1000 nM), and the plate was incubated for 1 h at
37 °C. Unbound radioligand was removed by two washes
with 250 μL TRIS buffered saline, and the remaining
radioactivity on the filter was measured in the gamma
counter. IC50 values were determined by fitting the
percent inhibition data using non-linear curve fitting
(Origin 6.1, Northampton, MA, USA).
Internalisation assay
For the determination of the receptor-mediated radioli-
gand uptake, CCK2+ and CCK2− cells were counted to a
density of 8 × 105 cells, seeded into 6-well plates (Greiner
Bio-One) and left to grow overnight at 37 °C. On the day
of the experiment to each 6-well either 150 μL of PBS/
0.5 % bovine serum albumin (BSA) solution (total series)
or 150 μL blocking solution (1 nM pentagastrin in PBS/
0.5 % BSA solution, non-specific series) for control were
added. Hereafter, 150 μL of the radiolabelled peptide was
added (1.3 nM AATZA-MG) into each well and incubated
for 1 h at 37 °C. To stop the internalisation process
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medium was removed and the supernatant collected
in plastic vials. The wells were washed two times with
1 mL DMEM medium containing 1 % fetal bovine
serum, and again, the supernatant was collected in
plastic vials (wash fraction).
The cells were rinsed twice with 1 mL ice-cold
Glycine-buffer and incubated for 5 min at RT to remove
membrane-bound radiolabelled peptide (membrane-
bound fraction). Subsequently, the cells were lysed by
addition of two times 1 mL of 2 M NaOH (internalised
fraction). All collected solutions were measured in the
gamma counter.
Biodistribution
All conducted animal experiments were in compliance
with the Austrian and Czech animal protection laws and
with approval of the Austrian Ministry of Science
(BMWFW-66.011/0049-WF/II/3b/2014) and the Czech
Ministry of Education Youth and Sports (MSMT-22421/
2013-12).
For normal biodistribution experiments 100 μL of
[68Ga]AAZTA-MG and [177Lu]AAZTA-MG (~0.3 nmol,
~0.4 μg peptide; 1 MBq/mouse) were simultaneously
injected into the tail vein of 8-to-10-week-old female
BALB/c mice (n = 4, Charles River laboratories, Sulzfeld,
Germany). The animals were sacrificed by cervical disloca-
tion 60 min post injection (p.i.). Organs (heart, stomach
spleen, liver, pancreas, kidneys and intestine), blood and
muscle tissue were removed and weighted. Activity of the
samples was measured simultaneously in the gamma
counter (177Lu as well as 68Ga) using the respective
gamma-energy windows, and the results expressed as per-
centage of injected dose per gram tissue (% ID/g).
For biodistribution studies in tumour xenograft-
bearing mice, female athymic BALB/c nude mice
(Charles River Laboratories, Sulzfeld, Germany) were
used (n = 4 per group). For the induction of tumour xe-
nografts, mice were injected subcutaneously near the
front shoulder with 2 × 106 cells (CCK2+) and the same
amount of CCK2− cells as a control subcutaneously in
100 μL DMEM+ 100 μL matrigel. The tumours were
allowed to grow until they had reached a volume of 0.3
to 0.6 cm3. 1 MBq (~0.3 nmol, ~0.4 μg peptide) of either
68Ga or 111In-labelled AAZTA-MG (n = 4) was adminis-
tered retroorbitally. After 60 min, mice were sacrificed,
and accumulated radioactivity was determined in organ
and tumour tissues and the results expressed as percent-
age of injected dose per gram tissue (% ID/g).
μPET/CT
The positron emission tomography (PET) and com-
puted tomography (CT) images were acquired with
an Albira PET/SPECT/CT small animal imaging system
(Bruker Biospin Corporation, Woodbridge, CT, USA).
Radiolabelled tracer ([68Ga]AAZTA-MG~ 5 MBq) was
administered retroorbitally into tumour xenograft-bearing
nude mice with a positive tumour at the left flank (2*106
CCK2+ cells) and a negative tumour at the right flank
(2*106 CCK2− cells). Mice were subsequently anaesthe-
tized with isoflurane (FORANE, Abbott Laboratories, Ab-
bott Park, IL, USA; 2 % flow rate) and were kept under
anaesthesia during the imaging process. Static PET/CT
imaging was carried out at 30, 45 and 60 min p.i. A 10-
min PET scan (axial FOV 148 mm) was performed,
followed by a CT scan (axial FOV 65 mm, 45 kVp,
400 μA, at 600 projections). Dynamic imaging was carried
out immediately after the injection of 68Ga labelled tracer
for 90 min (5-min PET scan per frame). Scans were
reconstructed with the Albira software (Bruker Bios-
pin Corporation, Woodbridge, CT, USA) using max-
imum likelihood expectation maximization (MLEM)
and filtered backprojection (FBP) algorithms [14, 15].
After reconstruction, the acquired data were viewed
and analysed with PMOD software (PMOD Technologies
Ltd., Zurich, Switzerland). The 3D images were obtained
using VolView software (Kitware, Clifton Park, NY, USA).
Results
Peptide synthesis
Solid-phase peptide synthesis of AAZTA-MG resulted in
1.5 mg of the conjugate which correlates to a theoretical
yield of 8.4 %. The purified peptide contained 4 % of oxi-
dised methionine which could not be removed by further
purification. ESI-MS [M+H] = 1516.67 [C71H97N13O22S;
exact mass: 1515.66 (calculated)] and HPLC traces of syn-
thesis products and the purified peptides are provided in
the Additional file 2, proving identity and purity of the
AAZTA-MG bioconjugate.
Radiolabelling
The AAZTA chelator showed excellent labelling per-
formance resulting in specific activities for 68Ga
(15.1 GBq/μmol), 177Lu (27.2 GBq/μmol) and 111In
(4.5 GBq/μmol), respectively, at pH of 4.0 to 4.5.
With all radionuclides, high radiochemical yields typically
of about 95 % could be achieved. Higher reaction temper-
atures (80 to 90 °C) showed no significant differences to
labelling at RT.
In vitro characterisation
Distribution coefficient (logD) for [68Ga]AAZTA-MG
was −3.6 (±0.18 SD; n = 6) and for [177Lu]AAZTA-MG
−3.73 (±0.17 SD; n = 2), respectively. The difference be-
tween these two was negligible, which indicates that the
peptide labelled with both radiometals is a highly
hydrophilic compound. The chelator AAZTA did not
dramatically reduce hydrophilicity. Stability tests of
[68Ga]AAZTA-MG (n = 3) showed an instability in human
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plasma and a slight transchelation with EDTA and DTPA.
This indicates some release of 68Ga, which also was ob-
served in the biodistribution study, where blood levels
with the 68Ga-compound were increased. In comparison,
[177Lu]AAZTA-MG (n = 3) showed a high stability in PBS,
EDTA and human plasma but some transchelation with
DTPA (Table 1).
Protein binding in human plasma was significantly
higher (p = 0.01 t test) for [68Ga]AAZTA-MG than for
[177Lu]AAZTA-MG. The protein-bound fraction in-
creased over time for the 68Ga-labelled compound from
9.5 to 15.8 %, indicating a slow release of 68Ga. In con-
trast to that, the 177Lu-labelled compound showed 4.5 %
protein binding with little variation over time.
For AAZTA-MG an IC50 value of 10.0 nM (±3.02 SD;
n = 6) was determined. Between [natLu] (n = 2; 9.44 ±
4.57 SD) and [natGa]-AAZTA-MG (n = 2; 8.18 ± 3.16) no
significant (p = 0.33 t test) difference could be determined
(Fig. 2). This indicates a high affinity of the AAZTA-MG
conjugate to the CCK2 receptor independently of the in-
troduced radiometal.
The internalisation assay of AAZTA-MG showed a
specific internalisation for both radiolabelled peptides,
but no relevant differences between [68Ga]AAZTA-MG
(7.70 ± 1.85 SD; n = 4) and [177Lu]AAZTA-MG (9.79 ±
2.68 SD; n = 5); in both cases surface bound activity
was <10 % of internalised activity. Blocking receptors
with pentagastrin reduced internalised activity below
1 % (non-specific binding) (Fig. 3).
In vivo characterisation
Biodistribution of labelled AAZTA-MG in normal mouse and
in a tumour xenograft mouse model
Biodistribution in BALB/c mice was determined 60 min
p.i. The radioactivity in different tissues of normal mice
(111In- vs. 68Ga-AAZTA-MG) and tumour xenografted
mice ([177Lu]- vs. [68Ga]-AAZTA-MG) are shown in
Table 2. Slight differences between the 68Ga-, 177Lu- and
111In-labelled peptide conjugates were observed:
[177Lu]AAZTA-MG and [111In]AAZTA-MG showed high
radioactivity accumulation in intestine and liver, which indi-
cates hepatobiliary excretion combined with low blood
levels. In contrast, [68Ga]AAZTA-MG showed high blood
levels correlating with the limited stability in vitro and high
protein binding of the 68Ga-compound. All three different
labelled compounds showed very low accumulation in
kidneys, comparable to other studies with MG11 [16].
Biodistribution of [68Ga]AATZA-MG and [111In]AATZA-
MG in the tumour xenograft model revealed a comparable
uptake in the CCK2+ tumour (68Ga = 1.5 %ID/g;
111In = 1.74 %ID/g), which is about fourfold higher
than in the CCK2− tumour (68Ga = 0.44 %ID/g; 111In =
0.33 %ID/g). This indicates a specific uptake in the
receptor-positive tumour tissue.
μPET-CT imaging
The μPET scans with [68Ga]AAZTA-MG showed good
targeting properties for CCK2− receptor-expressing tis-
sue corresponding with the data from biodistribution
studies. Radioactivity in kidneys and bladder could be
explained by the main renal excretion way. Also, specific
uptake in the CCK2+ tumours was observed with no up-
take in the CCK2− tumours. Images obtained at three
different time points (30, 45, and 60 min p.i.) are shown
in Fig. 4. The not only the kidneys and bladder shown were
clearly visualized but also the CCK2+ tumour. In contrast,
the CCK2− control tumour did not show any signal above
background. Over time, washout from kidneys and some
hepatobiliary excretion which was predicted from the bio-
distribution studies can be seen in the images.
A dynamic scan over 90 min but only in one slice of
PET scan without CT is shown in Fig. 5. High radio-
activity accumulation in the gall bladder and the tumour
was observed. Kidneys are not shown in this slice, but a
distribution in the gastrointestinal tract was seen over
time, which also confirms the biodistribution results.
Discussion
Choosing appropriate chelators gives radiopharmaceutical
science the opportunity to utilize different radionuclides
for diagnosis and to move established radiopharmaceuti-
cals towards therapeutic applications, enabling a theranos-
tic approach. Particularly, the chelator AAZTA shows a
novel versatile way of binding trivalent radionuclides,
providing mild radiolabelling conditions combined with
high-specific activities. So far only few data are available
on the properties of AAZTA conjugated biomolecules or
peptides.




A [%] B [%] C [%] D [%]
68Ga 177Lu 68Ga 177Lu 68Ga 177Lu 68Ga 177Lu
30 9.5 ± 0.4 4.9 ± 0.7 96 ± 2.1 99 ± 0.27 94 ± 1.6 92 ± 0.24 90 ± 3.2 97 ± 0.47
60 13.0 ± 1.2 4.9 ± 1.0 95 ± 2.7 98 ± 0.24 91 ± 1.6 87 ± 0.31 88 ± 2.1 98 ± 0.12
120 15.8 ± 1.8 3.7 ± 0.8 92 ± 5.5 98 ± 0.12 90 ± 0.5 77 ± 0.72 81 ± 7.9 97 ± 2.12
Data are shown as means ± SD
A serum protein binding; B stability in EDTA solution; C stability in DTPA solution; D stability in fresh human serum
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We chose the minigastrin analogue MG11 as a model
peptide, since gastrin is an interesting peptide for both
diagnostic and therapeutic applications in rare malignant
diseases (MTC, GIST) [17–19], and this particular pep-
tide was already used in combination with a number of
alternative chelating systems. Minigastrin represents a
peptide which is sensitive to extensive heating steps, as
methionine in its peptide sequence is prone to oxidation
leading to loss of receptor binding. In case of the chela-
tor AAZTA, no heating for radiolabelling is required,
and the problem of Met-oxidation can be almost elimi-
nated. In our study, all radiolabelling experiments could
be carried out at RT whereas for examples for DOTA
radiolabelling temperatures of more than 80 °C are usu-
ally needed.
Coupling of the AAZTA derivative to MG11 was suc-
cessful and proven by ESI-MS analysis. In this preliminary
study, no optimization of the synthesis was performed,
which is why relatively low yields were achieved; however,
these low yields were sufficient for the initial characterisa-
tion of the AAZTA-MG bioconjugate.
Radiolabelling results were overall very good and
showed quantitative radiolabelling at high-specific activ-
ities for 177Lu, 68Ga and 111In, respectively.
The logD values for [68Ga]AAZTA-MG and [177Lu]-
AAZTA-MG indicate a highly hydrophilic character of
Fig. 2 Displacement curves of [177Lu]CP04 binding to CCK2+ cell membranes using increasing concentrations of AAZTA-MG, [natGa]AAZTA-MG,
[natLu]AAZTA-MG and CP04 as control. Data are given as means ± SD
Fig. 3 Internalisation assay of [68Ga]AAZTA-MG and [177Lu]AAZTA-MG into CCK2+, CCK2− cells and CCK+ but blocked with Pentagastrin;
“Internalised” equates to internalisation ability of AAZTA-MG into the cells, and “Membrane bound” shows the adsorption to the external
membrane (membrane-bound fraction); Data are shown as means ± SD
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the complexes. This high hydrophilicity would typically
result in renal excretion of these peptides. Biodistribu-
tion and μPET-CT studies, however, revealed partly ex-
cretion via the hepatobiliary route. This may be a
consequence of the rather lipophilic linker (aliphatic C9
chain) used in the applied AAZTA derivatives or poten-
tially a result of hepatobiliary excretion of certain metab-
olites, considering the limited metabolic stability of
MG11-based peptide conjugates. Overall high stability in
different solutions was found for both radiometal labels,
with some decomposition in human plasma for
[68Ga]AAZTA-MG. This corresponds to the high blood
levels seen in the biodistribution study resulting in lower
tumour-to-background ratios in the μPET scans. This
was also confirmed by the higher protein-binding values
of [68Ga]AAZTA-MG as compared to its 177Lu counter-
part. The amount of 68Ga bound to serum proteins was
increasing over time which can be explained by trans-
chelation to transferrin due to a low complex stability.
This is in contrast to the findings of Baranjay et al. [20]
who reported excellent stability of AAZTA complexes
with stability constants (logK) of 22.18 for Ga3+ and
29.58 for In3+, which compares well with the stability
constant of 68Ga-DOTA with 21.3 and 23.9, respectively.
Waldron et al. [8] also found excellent stability of
[68Ga]-AAZTA complexes labelled at pH 4 and above.
However, they also describe unstable “kinetically
trapped” side products with low stability towards chal-
lenging solutions when labelled at pH 3.3 or lower. We
were not able to detect such side products by HPLC
with our [68Ga]-AAZTA-MG, radiolabelled at pH 4.5,
but cannot fully exclude their presence. Nevertheless, in
a recent comparison of different 68Ga-chelators, AAZTA
also showed some trend to release the radiometal in
transchelation experiments [21]. Despite the high
thermodynamic stability of AAZTA-metal chelates, in
comparison to DOTA, our studies indicate limitations in
kinetic stability in particular of [Ga]AAZTA complexes.
Therefore, dedicated applications with 68Ga chelators
like DOTA or NOTA may be preferable [22, 23]. In con-
trast to these findings for [177Lu]AAZTA-MG, only lim-
ited transchelation towards DTPA was observed, but no
indication for in vivo instability was found; also, protein
binding was neglectable.
The low IC50 values of AAZTA-MG showed high af-
finity for the CCK2 receptor, comparable to other results
of MG11 conjugated to DOTA [24]. Also, binding stud-
ies with the corresponding natGa- and natLu-labelled
compounds revealed no difference to the “metal-free”
peptide. Specific cell uptake after 60-min incubation re-
sulted in high-specific internalisation for both 68Ga- and
177Lu-labelled AAZTA-MG conjugates with no signifi-
cant difference between the two radiometals.
Biodistribution in normal BALB/c mice for 177Lu-la-
belled AAZTA-MG showed comparable low retention in
the kidneys but higher hepatobiliary excretion to
DOTA-MG11 [16]. Biodistribution of 68Ga- and 111In-la-
belled peptide was performed in BALB/c mice and
CCK2 tumour xenografted nude mice including μPET
studies. They revealed a significant (68Ga p = 0.007; 111In
p = 0.01 t test) difference in accumulation in CCK2+ vs.
CCK2− tumours (Table 2). Accumulation of peptide in
the CCK2+ tumour was well above background and
allowed to visualize the size of the tumour whereas
almost no radioactivity was detected in the CCK2− con-
trol tumour. These findings are overall comparable to
Table 2 Biodistribution data of AAZTA-MG labelled with different radiometals 1 h p.i. in different mouse models
111In-AAZTA-MG 68Ga-AAZTA-MG 177Lu-AAZTA-MG 68Ga-AAZTA-MG
CCK+/− BALB/c nude mice CCK+/− BALB/c nude mice BALB/c nude mice BALB/c nude mice
Blood 0.14 ± 0.03 0.38 ± 0.07 0.10 ± 0.09 2.90 ± 1.39
Spleen 0.14 ± 0.02 0.13 ± 0.01 0.11 ± 0.04 0.91 ± 0.34
Pancreas 0.13 ± 0.03 0.14 ± 0.02 0.12 ± 0.04 0.68 ± 0.28
Stomach 0.61 ± 0.11 0.47 ± 0.03 1.18 ± 0.13 0.95 ± 0.22
Intestine 8.62 ± 1.24 0.61 ± 0.08 19.14 ± 3.40 2.43 ± 0.32
Kidneys 1.79 ± 0.32 2.51 ± 0.66 1.39 ± 0.73 3.37 ± 0.43
Liver 2.46 ± 0.96 0.42 ± 0.07 3.05 ± 1.31 1.48 ± 0.26
Heart 0.12 ± 0.09 0.15 ± 0.04 0.07 ± 0.06 0.88 ± 0.32
Lung 0.21 ± 0.06 0.33 ± 0.07 0.14 ± 0.05 1.59 ± 0.47
Muscle 0.15 ± 0.18 0.07 ± 0.03 0.10 ± 0.17 0.36 ± 0.23
Femur 0.20 ± 0.11 0.11 ± 0.02 0.21 ± 0.18 0.74 ± 0.42
CCK2+ tumour (left flank) 1.74 ± 0.80 1.51 ± 0.53
CCK2− tumour (right flank) 0.33 ± 0.11 0.44 ± 0.06
Data are shown as %ID/g (mean ± SD, n = 4)
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other μPET scans with DOTA-MG analogues with the
exception of a higher uptake in the intestinal tract [22].
However, tumour uptake with 1.74 % ID/g was some-
what lower as for [111In]DOTA-MG11 with 3.04 % ID/g
in the same tumour model [16]. This cannot be ex-
plained by receptor binding or internalisation behaviour
which was comparable for both compounds, therefore
probably related to the differences in pharmacokinetics
by introducing another bifunctional chelator.
The tumour-to-kidney ratio of 0.9 for 111In and 0.6 for
68Ga is also comparable to DOTA conjugated to MG11
[25]. For [68Ga]AAZTA-MG, higher blood levels were
observed. This indicates an in vivo instability of the
[68Ga]AAZTA complex and correlates with our in vitro
tests, in particular, the high protein binding and instability
in human blood serum. It also resulted in a tumour-to-
blood ratio of about 4 with 1.5 % ID/g in CCK2+ tumours
as compared to a blood level of 0.4 % ID/g. This is in con-
trast to Tornesello et al. [25] who reported higher contrast
for the [68Ga]DOTA-MG11 over the [111In]DOTA-MG11.
For [111In]AAZTA-MG, the tumour-to-blood ratio was
considerably higher with a value of 12, which seems
slightly lower compared to [111In]DOTA-MG11 in the
same tumour model [16]. Again [111In]AAZTA-MG also
showed considerable higher excretion via the intestinal
tract, which could be explained by the aliphatic linker
used for AAZTA conjugation. This could be addressed by
modifying the structure of the AAZTA conjugate, e.g., by
truncating the spacer length between peptide and chelator
to eliminate intestinal activity. Also, conjugation to other
Fig. 4 Static μPET/CT images of [68Ga]-AAZTA-MG in CCK+/− tumour xenograft-bearing BALB/c nude mice 30 (a, d), 45 (b, e) and 60 (c, f) min
p.i.; coronal slices (a, b, c) and 3D volume rendered images (d, e, f). (supine position; injected dose ~5 MBq; anaesthesia: 2 % isoflurane; scan
duration: 10-min PET scan followed by 30-min CT scan)
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minigastrin peptide structures could improve tumour
targeting and pharmacokinetic properties, e.g. Laverman
et al. [16] showed that sic D-Glu in the amino acid se-
quence led to excellent tumour targeting combined with
increased metabolic stability and improved pharmacokin-
etics including low kidney retention.
Conclusions
In this study, we were able to couple the novel mesocyc-
lic chelator AAZTA to a minigastrin structure (MG11)
demonstrating its use for radiopharmaceutical applica-
tions. It was shown that radiolabelling with different
radiometals, including 68Ga, 177Lu and 111In, is possible
with a high yield at mild conditions and high-specific ac-
tivities comparable to the currently most widely used che-
lator DOTA. Some limitations were observed that require
further research efforts. Even though [68Ga]AAZTA-MG
showed good tumour targeting, the observed instability in
blood could be challenging for diagnostic imaging. Also,
the partial excretion of [177Lu]- and [111In]-AAZTA-MG
through the hepatobiliary route is certainly suboptimal for
a theranostic approach. Nevertheless AAZTA provides a
new opportunity for the development of radiopeptides
and other targeted radiopharmaceuticals, in particular for
use as a theranostic agent.
Additional files
Additional file 1: Figure S1. (molecular weight = 1,515 g/mol).
Additional file 2: Figure S2. HPLC chromatograms at different
purification steps. Top: Peptide after cleavage of the rink amid resin;
Middle: Fraction of the purification from the preparative HPLC; Bottom:
pure peptide with <4 % oxidised content.
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